CLSD Clearside Biomedical
- 1.270
- -0.010-0.78%
Clearside Biomedical News
Express News | Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
Clearside Biomedical(CLSD.US) Director Buys US$129.66K in Common Stock
$Clearside Biomedical(CLSD.US)$ Director Gibney Anthony S purchased 100K shares of common stock on Apr 17, 18, 2024 at an average price of $1.3 for a total value of $129.66K.Source: Announcement What
Express News | Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to Its Board of Directors
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million. Fresh2 Group
Clearside Biomedical(CLSD.US) Officer Buys US$48,000 in Common Stocks
$Clearside Biomedical(CLSD.US)$ Officer Chong Ngai Hang Victor purchased 30,000 shares of Common Stocks on Mar 20, 2024 at an average price of $1.6 for a total value of $48,000.Source: Announcement Wh
Clearside Biomedical Names Victor Chong Chief Medical Officer
Clearside Biomedical (CLSD) said Monday it appointed Victor Chong as chief medical officer. The company said Chong previously served as vice president and global head of Retina DAS at Johnson & Johnso
Press Release: Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Thr
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersPsyence Biomedical (NASDAQ:PBM) shares rose 52.9% to $1.59 during Thursday's regular session. The company's market cap stands at $21.2 million. Aptorum Gr (NASDAQ:APM) stock moved upwards by 43
Express News | HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Clearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial Progress
Clearside Biomedical Price Target Cut to $4.00/Share From $5.00 by Wedbush
Clearside Biomedical Price Target Cut to $4.00/Share From $5.00 by Wedbush
Clearside Biomedical Is Maintained at Outperform by Wedbush
Clearside Biomedical Is Maintained at Outperform by Wedbush
Wedbush Trims Clearside Biomedical's PT to $4 From $5 After Increased Share Count, Model Adjustments; Maintains Outperform Rating
Clearside Biomedical (CLSD) has an average rating of outperform and price targets ranging from $4 to $8, according to analysts polled by Capital IQ. Price: 1.61, Change: -0.03, Percent Change: -1.83
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR) and Clearside Biomedical (CLSD)
Express News | Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
Clearside Biomedical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/13/2024 166.67% Needham → $4 Reiterates Buy → Buy 11/14/2023 300% HC Wainwright & Co. → $6 Reiterates B
Buy Rating Affirmed for Clearside Biomedical on Innovative Treatments and Strong Financials
Analysis
Price Target
No Data
